☆ 4.4 Letter

Phase 3 results for vosaroxin/cytarabine in the subset of patients >= 60 years old with refractory/early relapsed acute myeloid leukemia

HAEMATOLOGICA (2018)

Get Full Text
Add to Collection

Journal

HAEMATOLOGICA
Volume 103, Issue 11, Pages E514-E518

Publisher

FERRATA STORTI FOUNDATION
DOI: 10.3324/haematol.2018.191361

Keywords

-

Categories

Hematology

Funding

  1. Sunesis Pharmaceuticals Inc. (South San Francisco, CA, USA)
  2. Sunesis Pharmaceuticals
  3. NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.